The Use of Nutropin Depot in HIV-infected Adult Males

Last updated: December 21, 2018
Sponsor: University of Texas Southwestern Medical Center
Overall Status: Trial Not Available

Phase

2/3

Condition

Aids And Aids Related Infections

Hiv/aids

Hiv Infections

Treatment

N/A

Clinical Study ID

NCT00286676
0103-045
  • Ages > 18
  • Male

Study Summary

This is a pilot study. We will treat 10 HIV-infected adults (1/2 with lipoatrophy) with GH depot for one year. Results will be compared to data from 10 HIV patients (1/2 with lipoatrophy), treated with Nutropin AQ subcutaneously. The primary endpoint of the study is to determine the effect of GH depot on body weight and lean tissue mass (LTM).

The secondary endpoints are to document changes in: 1) whole body protein turnover (WBPT), 2) gluconeogenesis, 3) bone mineral density and markers of bone turnover, 4) fat distribution (lipoatrophy), 5) thymus size, 6) T-cell subsets, and 7) TNF-µ levels. Adverse events, such as glucose intolerance and edema, will be monitored at every visit.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • adult males ≥ 18 years of age

  • mild to moderate lipoatrophy

  • stable protease inhibitor therapy for at least six months.

Exclusion

Exclusion Criteria:

  • Con-current supra-infection with acute illness defined by fever or bacterial culture

  • malignancy

  • females

  • diabetes mellitus

  • CNS tumors.

Study Design

Study Start date:
February 01, 2006
Estimated Completion Date:
February 01, 2006

Study Description

Patients will be recruited from the HIV clinics at University of Texas Southwestern Medical School and the Veterans Administration Hospital by direct invitation from Dr. Margolis (adult HIV clinic director and University director for the NIH-ACTG). We will recruit 20 HIV-infected adult males who have been treated with stable protease inhibitor therapy regimen for the past 6 months. One half of the subjects will have evidence of lipoatrophy (as defined by the ACTG29). Each subject will have baseline (BL) measures made, and then will start on GH depot or subcutaneous AQ. Patients will be followed every two weeks for the first six weeks, then every three months for the remainder of the study. Study parameters to be measured include (also see flow chart in appendix):

  • Baseline, 3, 6 and 12 months: OGTT, testosterone level, whole body protein turnover, hepatic glucose production and gluconeogenesis measures, DXA scan (for measuring lean tissue mass and bone density), bone mineral markers, resting energy expenditure, calorie count, T cell subsets, TNF µ levels.

  • Every 3 months: IGF-1 (will obtain every 2 weeks for first 6 weeks), body weight, and post-prandial glucose level.

  • Baseline, 6 and 12 months- CT scan for measurement of thymus size

Connect with a study center

  • Aston Ambulatory Care Center

    Dallas, Texas 75390
    United States

    Site Not Available

  • Parkland Health & Hospital System

    Dallas, Texas 75390
    United States

    Site Not Available

  • Veteran's Affairs Medical Center

    Dallas, Texas
    United States

    Site Not Available

+−

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.